Roche set to take its MS drug to regulators, but safety questions loom
Andrew Joseph covers well being, drugs, and the biopharma trade in Europe. You may attain Andrew on Sign at drewqjoseph.71.The ...
Andrew Joseph covers well being, drugs, and the biopharma trade in Europe. You may attain Andrew on Sign at drewqjoseph.71.The ...
Andrew Joseph covers well being, medication, and the biopharma trade in Europe. You may attain Andrew on Sign at drewqjoseph.71.In ...
Gilead Sciences exercised its possibility license a Kymera Therapeutics’ protein-degrading drug designed to get rid of the cancer-driving protein CDK2. ...
In a case that was billed as profits versus patients, India’s Supreme Court dismissed a petition in which Roche sought ...
Good morning, everyone, and welcome to another working week. We hope the weekend respite — which was longer than usual ...
Top of the morning to you, and a fine one it is. Clear blue skies and pleasant breezes are wafting ...
Roche is expanding its scope to a promising but competitive new obesity target, committing $1.65 billion up front to partner ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your ...
Credit: Pixabay/CC0 Public Domain Swiss pharmaceutical giant Roche said on Tuesday it agreed to buy US biopharma firm Poseida Therapeutics ...
An experimental Alzheimer’s therapy from Roche successfully cleared a protein that’s a hallmark of the disease from patients’ brains, the ...
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.